Sumatriptan Succinate Patent Expiration
Sumatriptan Succinate was first introduced by Glaxosmithkline
Sumatriptan Succinate Patents
Given below is the list of patents protecting Sumatriptan Succinate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Zembrace Symtouch | US10537554 | Pharmaceutical composition for treating migraine | Jan 29, 2036 | Tonix Meds |
Zembrace Symtouch | US11364224 | Pharmaceutical composition for treating migraine | Jan 29, 2036 | Tonix Meds |
Onzetra Xsail | US10076614 | Nasal delivery devices | Oct 20, 2034 | Currax |
Onzetra Xsail | US10478574 | Nasal administration | Nov 04, 2033 | Currax |
Zecuity | US9327114 | User-activated self-contained co-packaged iontophoretic drug delivery system | Oct 08, 2032 | Teva Branded Pharm |
Onzetra Xsail | US8978647 | Nasal delivery | Dec 06, 2030 | Currax |
Zecuity | US8983594 | Electronic control of drug delivery system | Nov 19, 2030 | Teva Branded Pharm |
Onzetra Xsail | US9649456 | Nasal administration | Oct 21, 2030 | Currax |
Onzetra Xsail | US8899229 | Powder delivery devices | Aug 18, 2030 | Currax |
Onzetra Xsail | US8550073 | Nasal delivery | Oct 22, 2029 | Currax |
Onzetra Xsail | US10076615 | Nasal delivery | Jul 30, 2029 | Currax |
Zecuity | US8366600 | Polyamine enhanced formulations for triptan compound iontophoresis | Apr 21, 2029 | Teva Branded Pharm |
Onzetra Xsail | US10722667 | Nasal administration | Dec 30, 2028 | Currax |
Onzetra Xsail | US8875704 | Nasal administration | Apr 07, 2028 | Currax |
Onzetra Xsail | US10398859 | Nasal delivery devices | Dec 19, 2027 | Currax |
Zecuity | US9272137 | Transdermal methods and systems for the delivery of anti-migraine compounds | Sep 07, 2027 | Teva Branded Pharm |
Alsuma | US7811254 | Autoinjector with needle depth adapter | Aug 26, 2027 | Meridian Medcl |
Zecuity | US7973058 | Transdermal methods and systems for the delivery of anti-migraine compounds | Apr 12, 2027 | Teva Branded Pharm |
Zecuity | US8155737 | Pharmacokinetics of iontophoretic sumatriptan administration | Apr 12, 2027 | Teva Branded Pharm |
Zecuity | US8470853 | Transdermal methods and systems for the delivery of anti-migraine compounds | Apr 12, 2027 | Teva Branded Pharm |
Zecuity | US8597272 | Pharmacokinetics of iontophoretic sumatriptan administration | Apr 12, 2027 | Teva Branded Pharm |
Zecuity | US9427578 | Pharmacokinetics of iontophoretic sumatriptan administration | Apr 12, 2027 | Teva Branded Pharm |
Onzetra Xsail | US10124132 | Nasal delivery | Mar 06, 2027 | Currax |
Sumavel Dosepro | US7776007 | Device for readying a needle free injector for delivery | Nov 22, 2026 | Endo Operations |
Sumavel Dosepro | US7901385 | Casing | Jul 31, 2026 | Endo Operations |
Onzetra Xsail | US11571531 | Powder delivery devices | Feb 23, 2026 | Currax |
Sumavel Dosepro | US8241243 | Needleless injector drug capsule and a method for filling thereof | Dec 25, 2025 | Endo Operations |
Onzetra Xsail | US8590530 | Nasal delivery devices | Sep 15, 2025 | Currax |
Onzetra Xsail | US9108015 | Nasal delivery devices | Sep 15, 2025 | Currax |
Onzetra Xsail | US7975690 | Nasal devices | Aug 18, 2025 | Currax |
Sumavel Dosepro | US8287489 | Device for readying a needle free injector for delivery | Dec 06, 2024 | Endo Operations |
Onzetra Xsail | US9119932 | Nasal delivery device |
Apr 23, 2024
(Expired) | Currax |
Onzetra Xsail | US8327844 | Nasal delivery method |
Oct 03, 2023
(Expired) | Currax |
Sumavel Dosepro | US8118771 | Needleless injector drug capsule and a method for filling thereof |
Aug 10, 2023
(Expired) | Endo Operations |
Onzetra Xsail | US8047202 | Nasal devices |
Jul 02, 2023
(Expired) | Currax |
Sumavel Dosepro | US8267903 | Casing |
Mar 18, 2023
(Expired) | Endo Operations |
Zecuity | US6745071 | Iontophoretic drug delivery system |
Feb 21, 2023
(Expired) | Teva Branded Pharm |
Sumavel Dosepro | US8241244 | Needleless injector drug capsule and a method for filling thereof |
Nov 21, 2022
(Expired) | Endo Operations |
Sumavel Dosepro | US8491524 | Needleless injector drug capsule and a method for filling thereof |
Nov 21, 2022
(Expired) | Endo Operations |
Sumavel Dosepro | US8343130 | Needleless injector |
Oct 18, 2022
(Expired) | Endo Operations |
Onzetra Xsail | US6715485 | Nasal delivery device |
Mar 03, 2020
(Expired) | Currax |
Onzetra Xsail | US8555877 | Nasal delivery device |
Mar 03, 2020
(Expired) | Currax |
Sumavel Dosepro | US6280410 | Method of filling a drug capsule and article produced thereby |
Mar 27, 2017
(Expired) | Endo Operations |
Sumavel Dosepro | US6135979 | Spring-powered dispensing device for medical purposes |
Mar 21, 2017
(Expired) | Endo Operations |
Sumavel Dosepro | US6251091 | Needleless injector drug capsule and filling method |
Dec 09, 2016
(Expired) | Endo Operations |
Sumavel Dosepro | US5957886 | Spring-Powered dispensing device |
Mar 08, 2016
(Expired) | Endo Operations |
Sumavel Dosepro | US6174304 | Filling device for a needless injector cartridge |
Dec 13, 2015
(Expired) | Endo Operations |
Sumavel Dosepro | US6681810 | Filling device for a needleless injector cartridge |
Dec 13, 2015
(Expired) | Endo Operations |
Sumavel Dosepro | US5891086 | Needle-less injector |
Jul 27, 2014
(Expired) | Endo Operations |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sumatriptan Succinate's patents.
Latest Legal Activities on Sumatriptan Succinate's Patents
Given below is the list recent legal activities going on the following patents of Sumatriptan Succinate.
Activity | Date | Patent Number |
---|---|---|
Expire Patent Critical | 10 Jun, 2024 | US9327114 |
Email Notification Critical | 24 Apr, 2024 | US10537554 |
Email Notification Critical | 24 Apr, 2024 | US11364224 |
Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US11364224 |
Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US10537554 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Apr, 2024 | US10537554 |
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Apr, 2024 | US11364224 |
Maintenance Fee Reminder Mailed Critical | 25 Dec, 2023 | US9327114 |
Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jul, 2023 | US10537554 |
Expire Patent Critical | 24 Apr, 2023 | US8983594 |
Sumatriptan Succinate's Family Patents
Explore Our Curated Drug Screens
Sumatriptan Succinate Generic API Manufacturers
Several generic applications have been filed for Sumatriptan Succinate. The first generic version for Sumatriptan Succinate was by Teva Parenteral Medicines Inc and was approved on Feb 6, 2009. And the latest generic version is by Baxter Healthcare Corp and was approved on Jan 19, 2023.
Given below is the list of companies who have filed for Sumatriptan Succinate generic, along with the locations of their manufacturing plants worldwide.
1. ANTARES PHARMA INC
Antares Pharma Inc has filed for 2 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Antares Pharma Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Dec 10, 2015 |
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Dec 10, 2015 |
Manufacturing Plant Locations New
Antares Pharma Inc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Antares Pharma Inc as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
2. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||
United States |
|
3. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Jan 19, 2023 |
4. CAPLIN
Caplin Steriles Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Caplin.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AP | Jul 13, 2021 |
Manufacturing Plant Locations New
Caplin's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Caplin as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
| |||
India |
|
5. COREPHARMA
Corepharma Llc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Corepharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Jun 19, 2012 |
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Jun 19, 2012 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jun 19, 2012 |
Manufacturing Plant Locations New
Corepharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Corepharma as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
6. DR REDDYS
Dr Reddys Laboratories Inc has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AB | Jan 29, 2014 |
7. DR REDDYS LABS INC
Dr Reddys Laboratories Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
8. ENDO OPERATIONS
Endo Operations Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Endo Operations.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Oct 9, 2009 |
9. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
(reference standard) | injectable | Prescription | SUBCUTANEOUS | AP | Apr 23, 2013 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
Country | City | Firm Name | ||||||
---|---|---|---|---|---|---|---|---|
India |
|
10. FOSUN PHARMA
Fosun Pharma Usa Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Fosun Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
Manufacturing Plant Locations New
Fosun Pharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fosun Pharma as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
11. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 2 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Sep 18, 2009 |
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Sep 18, 2009 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
|
12. HIKMA
Hikma Farmaceutica Portugal Sa has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Hikma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AP | Sep 16, 2013 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||
Portugal |
| |||||||||
Jordan |
|
13. HIKMA PHARMS
Hikma Pharmaceuticals has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Hikma Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | May 21, 2013 |
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | May 21, 2013 |
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | May 21, 2013 |
14. MYLAN
Mylan Pharmaceuticals Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Mylan.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Nov 2, 2009 |
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | Nov 2, 2009 |
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Nov 2, 2009 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||
India |
| |||||||||||||||||
Canada |
| |||||||||||||||||
Ireland |
|
15. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Apr 14, 2014 |
16. ORBION PHARMS
Orbion Pharmaceuticals Private Ltd has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Orbion Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
17. ROXANE
Roxane Laboratories Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Roxane.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
18. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Sandoz.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Feb 6, 2009 |
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Feb 6, 2009 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
Austria |
| |||||
United States |
| |||||
Spain |
| |||||
India |
|
19. STERISCIENCE SPECLTS
Steriscience Specialities Pte Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Steriscience Speclts.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Jul 28, 2010 |
20. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Sun Pharm.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AB | Jun 21, 2011 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||||||||||||||
India |
|
21. SUN PHARM INDS
Sun Pharmaceutical Industries Ltd has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
22. SUN PHARM INDS LTD
Sun Pharmaceutical Industries Ltd has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Feb 9, 2009 |
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | Aug 10, 2009 |
23. TEVA
Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Teva.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 50MG BASE | tablet | Discontinued | ORAL | N/A | Feb 9, 2009 |
EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Feb 9, 2009 |
EQ 25MG BASE | tablet | Discontinued | ORAL | N/A | Feb 9, 2009 |
Manufacturing Plant Locations New
Teva's manufacturing plants are situated in 6 countries - United States, India, Canada, Czech Republic, Ireland, Israel. Given below are the details of these plant locations as well as the firm names of Teva as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||
India |
| |||||||||
Canada |
| |||||||||
Czech Republic |
| |||||||||
Ireland |
| |||||||||
Israel |
|
24. TEVA PARENTERAL
Teva Parenteral Medicines Inc has filed for 2 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Teva Parenteral.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Feb 6, 2009 |
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Feb 6, 2009 |
Manufacturing Plant Locations New
Teva Parenteral's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Teva Parenteral as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
25. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Feb 6, 2009 |
26. WATSON LABS
Watson Laboratories Inc has filed for 3 different strengths of generic version for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Watson Labs.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 25MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 50MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 10, 2009 |
27. WEST-WARD PHARMS INT
West-ward Pharmaceuticals International Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by West-ward Pharms Int.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AP | Feb 6, 2009 |
28. WOCKHARDT
Wockhardt Ltd has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Wockhardt.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Prescription | SUBCUTANEOUS | AP | Feb 6, 2009 |
Manufacturing Plant Locations New
Wockhardt's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Wockhardt as present at those locations.
Country | City | Firm Name | ||||||
---|---|---|---|---|---|---|---|---|
India |
|
29. ZYDUS
Zydus Worldwide Dmcc has filed for 1 generic for Sumatriptan Succinate. Given below are the details of the strengths of this generic introduced by Zydus.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | injectable | Discontinued | SUBCUTANEOUS | N/A | Aug 11, 2010 |
Manufacturing Plant Locations New
Zydus's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Zydus as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||||||||||||||||
United States |
|